Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics (Nasdaq: GLUE), a clinical-stage biotech company developing molecular glue degrader (MGD)-based medicines, has announced its participation in two upcoming investor conferences:
1. Morgan Stanley 22nd Annual Global Healthcare Conference in New York, NY on September 4, 2024.
2. 2024 Wells Fargo Healthcare Conference in Boston, MA on September 5, 2024, where CEO Markus Warmuth, M.D., will participate in a fireside chat at 2:15 p.m. ET.
The fireside chat will be webcast and accessible through Monte Rosa's website, with an archived version available for 30 days after the presentation.
Monte Rosa Therapeutics (Nasdaq: GLUE), un'azienda biofarmaceutica in fase clinica che sviluppa farmaci basati su degrader a colla molecolare (MGD), ha annunciato la sua partecipazione a due prossime conferenze per investitori:
1. 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley a New York, NY, il 4 settembre 2024.
2. Conferenza sulla Salute Wells Fargo 2024 a Boston, MA, il 5 settembre 2024, dove il CEO Markus Warmuth, M.D., parteciperà a una chiacchierata informale alle 14:15 ET.
La chiacchierata sarà trasmessa in diretta e accessibile attraverso il sito web di Monte Rosa, con una versione registrata disponibile per 30 giorni dopo la presentazione.
Monte Rosa Therapeutics (Nasdaq: GLUE), una compañía biofarmacéutica en etapa clínica que desarrolla medicamentos basados en degradadores de pegamento molecular (MGD), ha anunciado su participación en dos próximas conferencias para inversores:
1. 22ª Conferencia Anual Global de Atención Médica de Morgan Stanley en Nueva York, NY, el 4 de septiembre de 2024.
2. Conferencia de Atención Médica Wells Fargo 2024 en Boston, MA, el 5 de septiembre de 2024, donde el CEO Markus Warmuth, M.D., participará en una charla informal a las 2:15 p.m. ET.
La charla se emitirá en vivo y será accesible a través del sitio web de Monte Rosa, con una versión archivada disponible durante 30 días después de la presentación.
몬테 로사 테라퓨틱스 (Nasdaq: GLUE), 분자 접착제 분해제(MGD) 기반 의약품을 개발하는 임상 단계의 생명공학 회사가 두 개의 다가오는 투자자 회의에 참가할 것이라고 발표했습니다:
1. 모건 스탠리 제22회 연례 글로벌 헬스케어 회의가 뉴욕, NY에서 2024년 9월 4일 열립니다.
2. 2024 웰스 파고 헬스케어 회의가 매사추세츠주 보스턴에서 2024년 9월 5일 열리며, CEO 마르쿠스 바무스(M.D.)가 오후 2시 15분 ET에 파이어사이드 채팅에 참석할 예정입니다.
파이어사이드 채팅은 웹캐스트로 방송될 예정이며, 몬테 로사 웹사이트를 통해 접근할 수 있으며 발표 후 30일 동안 아카이브된 버전이 제공됩니다.
Monte Rosa Therapeutics (Nasdaq: GLUE), une entreprise biopharmaceutique en phase clinique développant des médicaments basés sur des dégradants de colle moléculaire (MGD), a annoncé sa participation à deux prochaines conférences pour investisseurs :
1. 22ème Conférence Annuelle Mondiale sur les Soins de Santé de Morgan Stanley à New York, NY, le 4 septembre 2024.
2. Conférence sur les Soins de Santé Wells Fargo 2024 à Boston, MA, le 5 septembre 2024, où le PDG Markus Warmuth, M.D., participera à une discussion informelle à 14h15 ET.
La discussion sera diffusée en direct et accessible via le site web de Monte Rosa, avec une version archivée disponible pendant 30 jours après la présentation.
Monte Rosa Therapeutics (Nasdaq: GLUE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das auf molekularen Klebstoff-Abbauern (MGD) basierende Medikamente entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen angekündigt:
1. 22. Jahrestagung für globale Gesundheitsversorgung von Morgan Stanley in New York, NY am 4. September 2024.
2. Wells Fargo Gesundheitskonferenz 2024 in Boston, MA am 5. September 2024, bei der CEO Markus Warmuth, M.D., an einem Fireside-Chat um 14:15 Uhr ET teilnehmen wird.
Der Fireside-Chat wird live übertragen und über die Website von Monte Rosa zugänglich sein, mit einer archivierten Version, die 30 Tage nach der Präsentation zur Verfügung steht.
- None.
- None.
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in the following investor conferences:
- Morgan Stanley 22nd Annual Global Healthcare Conference (New York, NY) – September 4, 2024.
- 2024 Wells Fargo Healthcare Conference (Boston, MA) – Markus Warmuth, M.D., Chief Executive Officer, to participate in a fireside chat, September 5, 2024, at 2:15 p.m. ET.
A webcast of the fireside chat will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com, and an archived version will be made available for 30 days following the presentation.
About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond, and has a strategic collaboration with Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug. For more information, visit www.monterosatx.com.
Investors
Andrew Funderburk
ir@monterosatx.com
Media
Cory Tromblee, Scient PR
media@monterosatx.com
FAQ
When is Monte Rosa Therapeutics (GLUE) participating in the Morgan Stanley Healthcare Conference?
What is the date and time of Monte Rosa Therapeutics' (GLUE) fireside chat at the Wells Fargo Healthcare Conference?
How can investors access Monte Rosa Therapeutics' (GLUE) fireside chat webcast?
What type of medicines is Monte Rosa Therapeutics (GLUE) developing?
